• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Hiring antibodies as nanotechnology builders

Bioengineer by Bioengineer
December 3, 2019
in Science News
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Ella Marushchenko


What if we could use antibodies as functional tools for nanotechnology applications? A group of researchers at the University of Rome Tor Vergata started from this simple question and the results of their research are now published in Nature Communications.

Nanotechnology enables the design and fabrication of molecular structures of nanoscale dimensions that hold a great potential for several applications in the near future, including biomedicine. A convenient way to make such nanostructures is to employ synthetic DNA as the building material. These days it is possible to design and synthetize DNA strands that, by simple and predictable interactions, bind to each other just like Lego bricks, and form beautiful 2D and 3D geometries in a very controllable and precise fashion. To date, many nanoscale shapes have been created using DNA bricks, ranging from nanoboxes to more complex geometries, such as a nanoscale Monalisa. To allow potential applications of these nanostructures, however, it would be extremely important to design them so that their assembly and disassembly could be guided by molecular cues of clinical relevance.

Now a research group at the University of Rome, Tor Vergata has shown that it is possible to recruit antibodies as molecular builders to build or dismantle DNA nanostructures.

The function of antibodies in our body is to recognize and bind to a specific target (i.e. the antigen), which is often a foreign molecule or protein. For this reason, antibodies are ideal biomarkers because they are produced by our body to target foreign molecules in our blood. Each antibody has its own target and therefore does its job in a highly specific and precise way.

“This project started a couple of years ago when we realized that this amazing functionality of antibodies (recognize and bind to a specific molecule) could be repurposed for nanotech applications”, says Francesco Ricci, professor at the University of Rome Tor Vergata and senior author of the manuscript. “We had the idea of utilizing antibodies as molecular workers to build nanoscale structures”.

“To do this, we employed DNA bricks that bind to each other and form nanostructures of tubular shape”, says Simona Ranallo, a post-doc researcher in the group of Prof. Ricci and first author of the manuscript, “we then re-engineered such bricks with recognition tags (antigens) so that their assembly is initiated by a specific antibody. The nanotube structure can thus only built up when the antibody is present in the sample!”

“Antibodies are highly specialized workers” adds Ricci, “there are thousands of distinct antibodies in our body each recognizing its own antigen. We took advantage of this amazing feature and designed different bricks that can assemble with different specific antibodies”.

“We took a step further” continues Ricci, “we engineered our DNA bricks so that not only they assemble into the desired nanostructure in the presence of a specific antibody, but they can also be completely dismantled by a second antibody worker”.

This strategy demonstrates the possibility to design intelligent nanostructures that can be built and destroyed in the presence of a specific biomarker. This could have potential applications in the biomedical field, either in diagnostics or therapeutics.

###

Media Contact
Francesco Ricci
[email protected]
0039-067-269-4422

Related Journal Article

http://dx.doi.org/10.1038/s41467-019-13104-6

Tags: Chemistry/Physics/Materials SciencesNanotechnology/Micromachines
Share12Tweet8Share2ShareShareShare2

Related Posts

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

September 7, 2025

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

September 7, 2025

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

September 7, 2025

Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI Treatment

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    55 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.